All In Biotech

Drug Trial Radar · NCT04987658

Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder

A Phase 1, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OLZ/SAM in Pediatric Subjects (10-12 Years Old) With Bipolar I Disorder

Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Jul 22, 2021

Primary completion

Aug 11, 2023

Study completion Aug 11, 2023

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Aug 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 10 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability, and pharmacokinetics of olanzapine and samidorphan in clinically stable pediatric subjects (10 to 12 years old) with Bipolar I disorder following oral administration of multiple ascending doses of OLZ/SAM

Conditions

  • Bipolar I Disorder

Interventions

  • OLZ/SAMDrug

    Olanzapine and Samidorphan taken once daily over a max period of 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum plasma concentration observedTime frame: Up to 3 weeks
  2. Area under the plasma concentration-time curve over the 24-hour dosing intervalTime frame: Up to 3 weeks
  3. Time to reach maximum concentrationTime frame: Up to 3 weeks
  4. Incidence of Adverse EventsTime frame: Up to 6 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Decatur, Georgia

  • Alkermes Clinical Investigative Site

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.